The global Blood Testing Market was valued at USD 97.90 billion in 2024 and is expected to reach USD 169.15 billion by 2032, expanding at a CAGR of 7.08% from 2025 to 2032. Growth is being supported by the increasing need for early disease detection, rising healthcare expenditure, expanding preventive testing programs, and technological advances that are making blood-based diagnostics faster, more accurate, and increasingly accessible across healthcare settings.
Blood testing remains an essential component of modern healthcare, supporting the diagnosis, monitoring, and management of a broad range of conditions. Complete blood counts, glucose testing, infectious disease screening, cancer-related biomarkers, immunological testing, and molecular diagnostics are increasingly integrated into routine clinical workflows. The growing prevalence of diabetes, cardiovascular diseases, infectious diseases, and other chronic conditions is encouraging healthcare providers to expand diagnostic testing, while aging populations are creating additional demand for regular health assessments and disease monitoring.
The market is also benefiting from the increasing automation and digitalization of laboratory diagnostics. Advanced analyzers can process high testing volumes with improved consistency and reduced turnaround times, helping laboratories manage growing workloads. At the same time, point-of-care testing is expanding access to rapid diagnostic information outside traditional laboratories, including hospitals, physician offices, emergency departments, and other decentralized healthcare environments.
Sample Report: https://www.snsinsider.com/sample-request/1014
Technological Advancements Strengthen Market Opportunities
Automation is emerging as a major factor shaping the blood testing industry. Modern diagnostic platforms increasingly combine sample processing, testing, data management, and result interpretation into integrated laboratory workflows. These capabilities can improve operational efficiency while minimizing manual intervention and supporting reproducible testing outcomes. High-throughput analyzers are particularly important for large hospitals and centralized laboratories that need to process substantial numbers of samples.
Technological developments are also expanding the scope of blood-based diagnostics. Immunoassays, molecular testing, hematology analysis, and specialized diagnostic platforms are becoming more sophisticated, enabling healthcare professionals to obtain more detailed information from blood samples. The integration of laboratory information systems and digital technologies further supports efficient data handling and communication between diagnostic laboratories and healthcare providers.
Another important growth opportunity comes from decentralized testing. Portable and rapid diagnostic devices can provide results closer to the patient, supporting faster clinical decisions. This trend is particularly relevant in settings where access to centralized laboratory infrastructure is limited. Continued innovation in compact analyzers, rapid test kits, and connected diagnostic systems is expected to broaden the role of blood testing across different healthcare environments.
Rising Chronic Disease Burden Fuels Testing Demand
The increasing global burden of chronic diseases is creating sustained demand for blood-based diagnostics. Conditions such as diabetes, cardiovascular disorders, kidney disease, and various metabolic abnormalities often require regular laboratory monitoring. Blood tests help clinicians evaluate disease progression, assess treatment response, and identify potential complications, making diagnostic testing an integral part of long-term disease management.
Preventive healthcare is another significant market driver. Greater awareness of routine health screening is encouraging individuals and healthcare systems to emphasize early detection rather than relying exclusively on testing after symptoms emerge. Government screening initiatives, employer-sponsored health programs, and expanding healthcare access can further contribute to testing volumes.
Infectious disease surveillance also remains an important application area. Blood-based testing supports the identification of pathogens and antibodies and plays a critical role in screening programs. Continued improvements in diagnostic sensitivity and specificity are expected to support broader use across hospitals, laboratories, blood banks, and public health programs.
Competitive Landscape
The global blood testing market features a diverse competitive environment involving major diagnostic companies, laboratory service providers, medical technology manufacturers, and specialized testing firms. Leading participants are focusing on analyzer development, diagnostic assay innovation, automation, product expansion, and strategic collaborations to strengthen their market positions.
Danaher Corporation offers the DxH 520 Hematology Analyzer, while Trinity Biotech Plc provides solutions such as the Uni-Gold HIV Test and Hemoglobin A1c testing systems. Roche Diagnostics participates in the market with platforms including the Cobas 8000 Analyzer, while bioMérieux SA provides the VITEK 2 platform for diagnostic applications.
Quest Diagnostics offers the Quest Diabetes Panel, and Abbott has a broad diagnostics portfolio that includes Abbott Alinity and FreeStyle Libre. F. Hoffmann-La Roche AG markets Elecsys diagnostic solutions, while Bio-Rad Laboratories, Inc. offers the BioPlex 2200 platform. Biomerica, Inc. provides Hemoglobin A1c testing and rapid test kits.
Other notable participants include Becton, Dickinson and Company, with BD Vacutainer and BD FACS solutions; Siemens Healthineers, with Atellica and ADVIA platforms; and Thermo Fisher Scientific, with Orion Star A Series and cell and gene therapy-related solutions. Ortho Clinical Diagnostics, DiaSorin S.p.A., Sysmex Corporation, Hologic, Inc., PerkinElmer, Inc., Grifols, S.A., Werfen (Instrumentation Laboratory), and Mindray Medical International Limited also contribute to the competitive landscape.
Outlook
The blood testing market is positioned for continued expansion through 2032 as healthcare systems prioritize early diagnosis, disease monitoring, preventive care, and laboratory efficiency. Increasing chronic disease prevalence, technological advances, automation, point-of-care diagnostics, and broader access to healthcare are expected to remain key growth factors.
As diagnostic technologies become more integrated, connected, and capable of delivering rapid results, market participants are likely to focus increasingly on improving testing accuracy, workflow efficiency, accessibility, and scalability. These developments should create new opportunities across hospitals, clinical laboratories, diagnostic centers, research institutions, and decentralized healthcare settings.